Molecular and Genetic Analysis of Lung Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- Massachusetts General Hospital
- Enrollment
- 15000
- Locations
- 1
- Primary Endpoint
- Survival among patients at different stages of lung cancer and treatment will be measured using questionnaires along with medical chart data to monitor treatment and disease progression
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.
Detailed Description
Investigators also investigate how genetic variants may affect cancer treatment, at various stages of disease development, in order to determine prognostic and predictive factors for survival.
Investigators
David Christopher Christiani
Elkan Blout Professor at Harvard TH Chan School of Public Health, Professor of Medicine Harvard Medical School
Massachusetts General Hospital
Eligibility Criteria
Inclusion Criteria
- •healthy controls: participants without evidence of any cancer
- •cases: pathology proven primary lung cancer
Exclusion Criteria
- •younger than 18 years old
Outcomes
Primary Outcomes
Survival among patients at different stages of lung cancer and treatment will be measured using questionnaires along with medical chart data to monitor treatment and disease progression
Time Frame: 20 years
Study lung cancer development in a case control study. We will look at three separate outcome measures specified below
Secondary Outcomes
- Overall survival(20 years)
- Progression-free survival(20 years)
- Treatment toxicities(20 years)